Annual Report 2012

At a Glance
Medical
Main Products
• Injection- and infusion-related products
• Artifi cial organ-related products
• Highly functional products
• Dialysis-related products
• Diabetic-related products
Net Sales Ratio
68%
2012
(Millions of yen)
2011
Net Sales ¥145,082 ¥132,817
Operating Income ¥ 17,078 ¥ 18,437
7 Nipro Corporation Annual Report 2012
Our varied product line supports people all over the world who rely on medicine
to fi ght illnesses. We are a world leader in Dialyzer market share and we
have started our full-scale entry into the fi eld of diabetes-related products.
As one of the world’s top maker of medical devices, we aim to make further
steps for the future.
In the Japanese market, the sales
of our dialysis system drastically
increased from the previous year while
our dialysis-related products, such as
Dialyzer, showed stable growth. We
have also been working on reducing
the running cost of our plants as
well as enhancing our product range
through the development of high-value
products, which has contributed to
increases in profi t.
Dialysis-related products
Dialyzer
Diabetes-related products
Blood glucose meters
As for overseas sales, we have
been working to expand sales of
diabetes-related products through
Nipro Diagnostics Inc., which became
part of the Nipro Group in 2010. In
addition, we have acquired glassmanufacturing
companies in America
and Europe in order to establish a
fi rm foundation in the medical glass
business, with the aim of responding
to future demand. At the same time,
we have increased the proportion of
overseas manufactured products and
enabled direct transactions between
overseas plants and overseas
sales bases in order to reduce both
currency exchange risks and costs.
Artifi cial heart- and lung-
related products
Oxygenators